CoChat

Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model

Relizani, Karima, Griffith, Graziella, Echevarría, Lucía, Zarrouki, Faouzi, Facchinetti, Patricia, Vaillend, Cyrille, Leumann, Christian, Garcia, Luis, Goyenvalle, Aurélie · 2017 · Molecular Therapy - Nucleic Acids
Cited by 83

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtn.2017.06.013

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 42

  1. Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol., 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
  2. Goemans, 2011, Systemic administration of PRO051 in Duchenne’s muscular dystrophy, N. Engl. J. Med., 364, 1513, 10.1056/NEJMoa1011367 · DOI · Paper page
  3. Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3 · DOI · Paper page
  4. Mostacciuolo, 1987, Population data on benign and severe forms of X-linked muscular dystrophy, Hum. Genet., 75, 217, 10.1007/BF00281062 · doi:10.1007/bf00281062
  5. van Deutekom, 2007, Local dystrophin restoration with antisense oligonucleotide PRO051, N. Engl. J. Med., 357, 2677, 10.1056/NEJMoa073108 · DOI · Paper page
  6. Kinali, 2009, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol., 8, 918, 10.1016/S1474-4422(09)70211-X · DOI · Paper page
  7. Aartsma-Rus, 2017, FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga, Nucleic Acid Ther., 27, 1, 10.1089/nat.2016.0657 · DOI · Paper page
  8. Lu, 2014, What can we learn from clinical trials of exon skipping for DMD?, Mol. Ther. Nucleic Acids, 3, e152, 10.1038/mtna.2014.6 · DOI
  9. Straub, 2016, Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy, Lancet Neurol., 15, 882, 10.1016/S1474-4422(16)30035-7 · DOI
  10. Stein, 2016, Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice, Mol. Ther., 24, 1884, 10.1038/mt.2016.188 · DOI · Paper page
  11. Goyenvalle, 2015, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nat. Med., 21, 270, 10.1038/nm.3765 · DOI · Paper page
  12. Goyenvalle, 2016, Therapeutic potential of Tricyclo-DNA antisense oligonucleotides, J Neuromuscul Dis, 3, 157, 10.3233/JND-160146 · doi:10.3233/jnd-160146
  13. Renneberg, 2002, Watson-Crick base-pairing properties of tricyclo-DNA, J. Am. Chem. Soc., 124, 5993, 10.1021/ja025569+ · DOI
  14. Ittig, 2011, Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes, Nucleic Acids Res., 39, 373, 10.1093/nar/gkq733 · DOI
  15. Renneberg, 2002, Antisense properties of tricyclo-DNA, Nucleic Acids Res., 30, 2751, 10.1093/nar/gkf412 · doi:10.1093/nar/gkf412
  16. Murray, 2012, TricycloDNA-modified oligo-2′-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues--a comparative study of oligonucleotide length, design and chemistry, Nucleic Acids Res., 40, 6135, 10.1093/nar/gks273 · DOI · Paper page
  17. Moulton, 2010, Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy, Biochim. Biophys. Acta, 1798, 2296, 10.1016/j.bbamem.2010.02.012 · DOI · Paper page
  18. Frazier, 2014, Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide, Toxicol. Pathol., 42, 923, 10.1177/0192623313505781 · doi:10.1177/0192623313505781
  19. Aartsma-Rus, 2014, Antisense-mediated exon skipping: networking to meet opportunities and to overcome challenges, Nucleic Acid Ther., 24, 1, 10.1089/nat.2014.1500 · DOI
  20. Godfrey, 2017, Delivery is key: lessons learnt from developing splice-switching antisense therapies, EMBO Mol. Med., 9, 545, 10.15252/emmm.201607199 · DOI
  21. Mann, 2002, Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy, J. Gene Med., 4, 644, 10.1002/jgm.295 · DOI
  22. Kohler, 2005, Quality of life, physical disability, and respiratory impairment in Duchenne muscular dystrophy, Am. J. Respir. Crit. Care Med., 172, 1032, 10.1164/rccm.200503-322OC · DOI · Paper page
  23. Lidov, 1993, The distribution of dystrophin in the murine central nervous system: an immunocytochemical study, Neuroscience, 54, 167, 10.1016/0306-4522(93)90392-S · DOI · Paper page
  24. Knuesel, 2000, Differential expression of utrophin and dystrophin in CNS neurons: an in situ hybridization and immunohistochemical study, J. Comp. Neurol., 422, 594, 10.1002/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q · DOI
  25. Miranda, 2015, Altered social behavior and ultrasonic communication in the dystrophin-deficient mdx mouse model of Duchenne muscular dystrophy, Mol. Autism, 6, 60, 10.1186/s13229-015-0053-9 · DOI · Paper page
  26. Sekiguchi, 2009, A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice, Brain, 132, 124, 10.1093/brain/awn253 · DOI · Paper page
  27. Frazier, 2015, Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective, Toxicol. Pathol., 43, 78, 10.1177/0192623314551840 · DOI · Paper page
  28. Henry, 2002, Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide, Int. Immunopharmacol., 2, 1657, 10.1016/S1567-5769(02)00142-X · DOI
  29. Agrawal, 2004, Role of Toll-like receptors in antisense and siRNA [corrected], Nat. Biotechnol., 22, 1533, 10.1038/nbt1042 · DOI
  30. Dirin, 2013, Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides, Expert Opin. Biol. Ther., 13, 875, 10.1517/14712598.2013.774366 · DOI · Paper page
  31. Swayze, 2007, Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals, Nucleic Acids Res., 35, 687, 10.1093/nar/gkl1071 · DOI · Paper page
  32. Vaidya, 2008, Biomarkers of acute kidney injury, Annu. Rev. Pharmacol. Toxicol., 48, 463, 10.1146/annurev.pharmtox.48.113006.094615 · DOI · Paper page
  33. Zhang, 2015, The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse, Toxicol. Rep., 2, 838, 10.1016/j.toxrep.2015.05.008 · DOI
  34. Bladen, 2015, The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations, Hum. Mutat., 36, 395, 10.1002/humu.22758 · DOI · Paper page
  35. Ittig, 2004, Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA, Nucleic Acids Res., 32, 346, 10.1093/nar/gkh187 · DOI
  36. Chaussenot, 2015, Cognitive dysfunction in the dystrophin-deficient mouse model of Duchenne muscular dystrophy: a reappraisal from sensory to executive processes, Neurobiol. Learn. Mem., 124, 111, 10.1016/j.nlm.2015.07.006 · DOI · Paper page
  37. Kamola, 2015, In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization, Nucleic Acids Res., 43, 8638, 10.1093/nar/gkv857 · DOI · Paper page
  38. Lindow, 2012, Assessing unintended hybridization-induced biological effects of oligonucleotides, Nat. Biotechnol., 30, 920, 10.1038/nbt.2376 · DOI
  39. Zhou, 2008, Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium, Toxicol. Sci., 101, 159, 10.1093/toxsci/kfm260 · DOI · Paper page
  40. Goyenvalle, 2012, Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping, Hum. Mol. Genet., 21, 2559, 10.1093/hmg/dds082 · DOI
  41. Mattison, 2012, Role of circulating fibroblast growth factor-2 in lipopolysaccharide-induced acute kidney injury in mice, Pediatr. Nephrol., 27, 469, 10.1007/s00467-011-2001-z · DOI
  42. Aartsma-Rus, 2003, Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients, Hum. Mol. Genet., 12, 907, 10.1093/hmg/ddg100 · DOI · Paper page

Cited by

See all 83

Metadata

Authors
Relizani, K., Griffith, G., Echevarría, L., Zarrouki, F., Facchinetti, P., Vaillend, C., Leumann, C., Garcia, L., & Goyenvalle, A.
Venue
Molecular Therapy - Nucleic Acids
Publisher
Elsevier BV
Published
2017-09
Volume
8
Pages
144-157
ISSN
2162-2531
Cited by
83
References
2
Language
en
Licence
Funders
  • Agence Nationale de la Recherche (ANR-14-CE13-0037)
  • Duchenne Parent Project
  • Association Française contre les Myopathies
  • Institut National de la Santé et de la Recherche Médicale

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.